Skip to main content
Premium Trial:

Request an Annual Quote

Greg Lucier, Frank Laukien, Michael Treble

Invitrogen president and CEO Greg Lucier saw his total compensation more than double in 2007 compared to 2006 as his stock awards and non-equity incentive plan compensation rose sharply last year, according to a proxy statement filed with the US Securities and Exchange Commission this week.
In 2007, Lucier’s total compensation came in at $11,068,812, up from $5,403,478. His base salary rose to $910,000 last year from $904,615 in 2006 while stock awards given to him jumped to more than $5 million from $1.3 million the year before. Non-equity incentive plan compensation rose more than seven-fold to more than $2 million in 2007 from $287,674 in 2006 as the company underwent a financial turnaround.
Last year, Invitrogen posted a profit of $143.2 million, compared to a loss of $191 million the year before. Revenues climbed to $1.3 billion, up 11 percent from $1.2 billion in 2006.
In March, Invitrogen increased Lucier’s base pay to $975,000, retroactive to Jan. 1.
In 2007, each of Invitrogen’s nine board members received between $207,805 and $249,690 in total compensation, according to the filing.

Bruker CEO Frank Laukien made $599,150 in total compensation in 2007, down 4.4 percent from a year ago, according to a document filed with the US Securities and Exchange Commission this week. In 2006 his compensation totaled $626,440.
His compensation in 2007 included a base salary of $306,500, compared to a base salary of $295,000 in 2006. For 2008, his base salary is $425,000 “reflecting the increased responsibilities he will have due to the acquisition of the Bruker BioSpin” business in February, the company said in its filing.

Michael Treble has been elected chairman of Axela’s board, the company said this week.
Treble has been a director and member of Axela’s audit committee since 2004. He is currently president of Ibis BioSciences, and was formerly COO and director of Third Wave Technologies, and president and CEO of NimbleGen Systems.
Axela is a privately held protein interaction firm based in Toronto.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.